



STAY CURRENT with FDA-Approved Immunotherapy Treatments

Free for healthcare professionals, students, patients and patient advocates, the Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) programs are CME-, CNE-, CPE- and MOC-certified and presented by local authorities in tumor immunology and cancer immunotherapy.

All healthcare professionals in the clinical setting, students, patients and patient advocates attend for FREE! For more information or to register for Charleston’s upcoming ACI, please visit sitcancer.org/charleston

CHARLESTON, S.C. ACI Program Information

Saturday, Feb. 1, 2020
8:30 a.m.–1:20 p.m. EST

Charleston Marriott
170 Lockwood Blvd.
Charleston, SC 29403

Organizers:
David M. Neskey, MD – *MUSC Hollings Cancer Center*
Chrystal M. Paulos, PhD – *MUSC Hollings Cancer Center*
Jessica Thaxton, PhD, MSCR – *Medical University of South Carolina*

Register yourself and invite a colleague to ensure your team is up to date on the latest FDA-approved immunotherapy treatments

To register, please visit:
sitcancer.org/charleston

CHARLESTON, S.C. ACI Program Takeaways

In addition to networking with fellow colleagues, attending ACI programs will cover how to:

- Treat patients with FDA-approved immunotherapies
- Recognize common and uncommon toxicities in immunotherapy patients and provide solutions/adjustments in treatment to address them
- Interpret new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
- Anticipate forthcoming immunotherapy trends/treatments/trials and how they impact your patients and practices
- Employ strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice

Attendees will be able to connect with regional immunotherapy experts during these interactive in-person programs, in subsequent quarterly webinars and through a dedicated SITC CONNECT online community.

AMA Credit Designation

This activity has been approved for *AMA PRA Category 1 Credit(s)™*.

Pharmacist Credit Designation

This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Nursing Credit Designation

This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.



The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.